Patient Enrollment Form

For patients 12 years of age and older living with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis (gMG)

Disease control that lasts* in a 24-week clinical trial1,2

*IMAAVY + SOC vs placebo + SOC, as measured by mean change in MG-ADL total score from baseline to Weeks 22, 23, and 24 (-4.7 vs -3.3, P=0.002).1,2

Learn more

The first and only fully human FcRn-blocking mAb for long-lasting, targeted binding1,2

  • IMAAVY demonstrated IgG reduction over 24 weeks
  • Based on in vivo and/or in vitro studies.3 The clinical significance of these characteristics is not fully known
Learn about the MOA

IMAAVY + SOC: superior disease control that lasts† in a 24-week clinical trial vs placebo + SOC1,2

†As measured by mean change in activities of daily living (MG-ADL) and muscle weakness (QMG):
  • MG-ADL total score from baseline to Weeks 22, 23, and 24: -4.7-point mean reduction with IMAAVY + SOC vs -3.3 for placebo + SOC, P=0.002
  • QMG total score from baseline to Weeks 22 and 24: -4.9-point mean reduction with IMAAVY + SOC vs -2.1 for placebo + SOC, P<0.001
Review efficacy data

IMAAVY + SOC was evaluated to 120 weeks in an ongoing OLE study4

  • Efficacy and safety results were consistent with those seen in the double-blind phase
Review OLE data

A proven safety profile over
24 weeks1,2

  • The most common adverse reactions (≥10%) in patients with gMG treated with IMAAVY were respiratory tract infections, peripheral edema, and muscle spasms
  • Patients on IMAAVY may experience serious adverse events such as infections, hypersensitivity reactions, and infusion-related reactions
Review safety data

AChR=acetylcholine receptor; FcRn=neonatal fragment crystallizable receptor; IgG=immunoglobulin G; mAb=monoclonal antibody; MG-ADL=Myasthenia Gravis Activities of Daily Living; MOA=mechanism of action; MuSK=muscle-specific tyrosine kinase; OLE=open-label extension; QMG=Quantitative Myasthenia Gravis; SOC=standard of care.

IMAAVY® (nipocalimab-aahu) Transparent LogoIMAAVY® (nipocalimab-aahu) Transparent Logo

Once you’ve made the decision to prescribe IMAAVY

Sign your patients up for support to help begin their IMAAVY journey

Enroll your patients today
IMAAVY® (nipocalimab-aahu) Transparent Logo

References: 1. IMAAVY [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105–116. doi:10.1016/S1474-4422(24)00498-8 3. Seth NP, Xu R, DuPrie M, et al. Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. MAbs. 2025;17(1):1–22. doi:10.1080/19420862.2025.2461191 4. Antozzi C, Vu T, Ramchandren S, et al. Long-term safety and efficacy of nipocalimab: approximately 2 years follow-up results from the open-label extension phase of Vivacity-MG3 study. Poster presented at: American Academy of Neurology (AAN) Annual Meeting; April 18–22, 2026; Chicago, IL.